ReviewCancer medicine2024
Regulation of regulatory T cells and tumor-associated macrophages in gastric cancer tumor microenvironment.
Review in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 23 citations in OpenAlex.
- Helicobacter pylori promote M1 macrophage polarization via JAK3-mediated activation of the SOCS3/IL2RA axis to suppress host immunity.Archives of microbiology · 2026Article
- Article
- Tumor microenvironment in gastric cancer immune tolerance and its therapeutic relevance in immunomodulation (Review).Oncology letters · 2026Review
- Immunomodulatory effects of primed amniotic fluid-derived mesenchymal stem/stromal cells with IFN-γ from unexplained recurrent miscarriage sources.Scientific reports · 2026Article
- Durable response to FOLFOX plus serplulimab in AFP-producing gastric adenocarcinoma with liver metastases: a case report and literature review.Frontiers in immunology · 2026Review
- TAM-targeted nanomedicine in cancer: biological basis, therapeutic strategies, and translational perspectives.Theranostics · 2026Review
- Targeting regulatory T cell plasticity in gastric cancer: a unified bimodal model and precision immunotherapy paradigm: a hypothesis-generating review.Frontiers in oncology · 2026Article
- Immune modulation in gastric cancer: from macrophage polarization to immunotherapy.Frontiers in immunology · 2026Review
- Single-cell and spatial landscape reveals impaired tertiary lymphoid structure maturation inFrontiers in immunology · 2026Article
- Regulating the regulators via targeting CD38 in the tumor microenvironment.Frontiers in immunology · 2026Review
- NKAIN1 expression relates to the immune evasion and prognosis of gastric cancer.Scientific reports · 2025Article
- Reprogramming natural killer cells in the tumor microenvironment: Challenges and therapeutic opportunities.Cytokine & growth factor reviews · 2025Review
- TRIM32 promotes tumor immune evasion and impedes Anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer.Journal of translational medicine · 2025Article
- Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors.Cancer medicine · 2025Review
- NLRP3 inflammasome expression affects immune cell infiltration and clinical prognosis inMolecular medicine reports · 2025Article
- Oxidative Stress and Inflammation: Drivers of Tumorigenesis and Therapeutic Opportunities.Antioxidants (Basel, Switzerland) · 2025Review
- Extracellular matrix: unlocking new avenues in cancer treatment.Biomarker research · 2025Review
- Impact of radiotherapy on secondary lung cancer risk and survival in elderly female breast cancer survivors.Translational oncology · 2025Article
- Helicobacter pylori CagA promotes gastric cancer immune escape by upregulating SQLE.Cell death & disease · 2025Article
- Role and value of the tumor microenvironment in the progression and treatment resistance of gastric cancer (Review).Oncology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
introductionDespite advancements in the methods for prevention and early diagnosis of gastric cancer (GC), GC continues to be the fifth in incidence among major cancers and the third most common cause of cancer-related death. The therapeutic effects of surgery and drug treatment are still unsatisfied and show notable differences according to the tumor microenvironment (TME) of GC.
methodsThrough screening Pubmed, Embase, and Web of Science, we identified and summarized the content of recent studies that focus on the investigation of Helicobacter pylori (Hp) infection, regulatory T cells (Tregs), and tumor-associated macrophages (TAMs) in the TME of GC. Furthermore, we searched and outlined the clinical research progress of various targeted drugs in GC treatment including CTLA-4, PD-1\PD-L1, and VEGF/VEGFR.
resultsIn this review, the findings indicate that Hp infection causes local inflammation and leads to immunosuppressive environment. High Tregs infiltration in the TME of GC is associated with increased induction and recruitment; the exact function of infiltrated Tregs in GC was also affected by phenotypes and immunosuppressive molecules. TAMs promote the development and metastasis of tumors, the induction, recruitment, and function of TAMs in the TME of gastric cancer are also regulated by various factors.
conclusionDiscussing the distinct tumor immune microenvironment (TIME) of GC can deepen our understanding on the mechanism of cancer immune evasion, invasion, and metastasis, help us to reduce the incidence of GC, and guide the innovation of new therapeutic targets for GC eventually.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.